Abstract:Noroviruses are the major cause of epidemic gastroenteritis in humans, causing ~20 million cases annually, resulting in more than 70,000 hospitalizations and 570-800 deaths in the United States alone. The T=3 icosahedral calicivirus capsid is composed of viral protein 1 (VP1) with three major domains: the N-terminus (N), shell (S), and C-terminal protruding (P) domains. The S domain forms a shell around the viral RNA genome, while the P domains dimerize to form protrusions on the capsid surface. The P domain is subdivided into P1 and P2 subdomains, with the latter containing the binding sites for cellular receptors and neutralizing antibodies. Mouse norovirus (MNV) is a widely used system for study of norovirus biology since we have a cell culture system, reverse genetic tools, and small animal model to eventually correlate structural information to whole animal pathology Mouse norovirus is a surprisingly dynamic virus that switches between receptor and antibody binding structures depending upon the in-vivo environment. In the circulation, the P domain floats above the shell by more than 15Å and the P domain loops (A’B’/E’F’) at the very tip are splayed apart in an ‘open’ conformation that antibodies learn to recognize. Upon ingestion, the low pH environment with high metal and bile salt concentrations in the alimentary canal each independently trigger the P domains to rotate 90° and contract by 15 Å onto the capsid surface. This hides any epitopes at base of the P domain. During this reversible collapse, the two P domains within the dimer rotate about each other and the A’B’/E’F’ loops adopt the ‘closed’ conformation. This opens the receptor binding site while burying the epitopes at the tip of the P domain. Therefore, rather than only depending on escape mutations to block antibody binding, MNV aggressively uses host conditions to remodel itself to enhance receptor binding while blocking antibody recognition. This review will describe the structural processes and biological consequences of the virus responding to activating host cues in the gut while these same triggers bury the epitopes presented in the circulation. This is an aggressive and unique mode of immune escape that has been subsequently shown in other viruses such as COVID-19. Therefore, a deeper understanding of the dynamic processes of virus capsids will improve vaccine design by understanding how to present the epitope conformations at the site of infection rather than what is presented to the immune system.

Norovirus immunology: Of mice and mechanisms

Human norovirus infection and the acute serum cytokine response

Advances in Norovirus Biology

Recent advances in human norovirus research and implications for candidate vaccines

Heterotypic humoral and cellular immune responses following Norwalk virus infection

Understanding the relationship between norovirus diversity and immunity

Norovirus encounters in the gut: multifaceted interactions and disease outcomes

Human Norovirus: Experimental Models of Infection

Advances in human norovirus research: Vaccines, genotype distribution and antiviral strategies

Identification of Immune and Viral Correlates of Norovirus Protective Immunity through Comparative Study of Intra-Cluster Norovirus Strains

The major targets of acute norovirus infection are immune cells in the gut-associated lymphoid tissue

New Interventions Against Human Norovirus: Progress, Opportunities, and Challenges

Progress towards the prevention and treatment of norovirus infections

Patterns of the within-host evolution of human norovirus in immunocompromised individuals and implications for treatment

Norovirus: Facts and Reflections from Past, Present, and Future

Norovirus antivirals: Where are we now?

Mouse Norovirus Uses Host Metabolites to Enhance Receptor Binding and Evade Immune Recognition

Activation of Nod2 signaling upon norovirus infection enhances antiviral immunity and susceptibility to colitis

Animals as Reservoir for Human Norovirus

Norovirus Vaccines: Current Clinical Development and Challenges